CA3070264A1 - Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue - Google Patents

Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue Download PDF

Info

Publication number
CA3070264A1
CA3070264A1 CA3070264A CA3070264A CA3070264A1 CA 3070264 A1 CA3070264 A1 CA 3070264A1 CA 3070264 A CA3070264 A CA 3070264A CA 3070264 A CA3070264 A CA 3070264A CA 3070264 A1 CA3070264 A1 CA 3070264A1
Authority
CA
Canada
Prior art keywords
antibody
bst1
cancer
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3070264A
Other languages
English (en)
French (fr)
Inventor
Cecilia SIMONELLI
Andrea PELLACANI
Monica Binaschi
Daniela Bellarosa
Corrado CARRISI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlin Chemie AG
Original Assignee
Berlin Chemie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie AG filed Critical Berlin Chemie AG
Publication of CA3070264A1 publication Critical patent/CA3070264A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA3070264A 2017-07-21 2018-07-20 Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue Pending CA3070264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1711785.4A GB201711785D0 (en) 2017-07-21 2017-07-21 Antibodies
GB1711785.4 2017-07-21
PCT/EP2018/069768 WO2019016371A1 (en) 2017-07-21 2018-07-20 PHARMACEUTICAL ASSOCIATIONS COMPRISING ANTI-BST-1 ANTIBODY AND A CYTIDINE ANALOG

Publications (1)

Publication Number Publication Date
CA3070264A1 true CA3070264A1 (en) 2019-01-24

Family

ID=59771583

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3070264A Pending CA3070264A1 (en) 2017-07-21 2018-07-20 Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue

Country Status (22)

Country Link
US (1) US20200231694A1 (enExample)
EP (1) EP3655033A1 (enExample)
JP (1) JP2020527594A (enExample)
KR (1) KR20200032162A (enExample)
CN (1) CN111132697A (enExample)
AR (1) AR112460A1 (enExample)
AU (1) AU2018303241A1 (enExample)
BR (1) BR112020001320A2 (enExample)
CA (1) CA3070264A1 (enExample)
CL (1) CL2020000175A1 (enExample)
CO (1) CO2020001792A2 (enExample)
EA (1) EA202090333A1 (enExample)
GB (1) GB201711785D0 (enExample)
IL (1) IL272096A (enExample)
MA (1) MA49627A (enExample)
MX (1) MX2020000752A (enExample)
PH (1) PH12020550024A1 (enExample)
SG (1) SG11202000390TA (enExample)
TW (1) TW201907952A (enExample)
UY (1) UY37815A (enExample)
WO (1) WO2019016371A1 (enExample)
ZA (1) ZA202000881B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
BR112013032621A2 (pt) * 2011-06-28 2017-01-24 Oxford Biotherapeutics Ltd anticorpos
GB201806084D0 (en) * 2018-04-13 2018-05-30 Berlin Chemie Ag Antibodies
CN118178645A (zh) * 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法

Also Published As

Publication number Publication date
UY37815A (es) 2019-02-28
IL272096A (en) 2020-03-31
CN111132697A (zh) 2020-05-08
GB201711785D0 (en) 2017-09-06
KR20200032162A (ko) 2020-03-25
US20200231694A1 (en) 2020-07-23
PH12020550024A1 (en) 2021-02-15
MX2020000752A (es) 2020-08-17
MA49627A (fr) 2020-05-27
EA202090333A1 (ru) 2020-05-06
AR112460A1 (es) 2019-10-30
BR112020001320A2 (pt) 2020-08-11
TW201907952A (zh) 2019-03-01
ZA202000881B (en) 2021-08-25
JP2020527594A (ja) 2020-09-10
CL2020000175A1 (es) 2020-06-12
EP3655033A1 (en) 2020-05-27
AU2018303241A1 (en) 2020-02-20
CO2020001792A2 (es) 2020-07-31
WO2019016371A1 (en) 2019-01-24
SG11202000390TA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
AU2014203781B2 (en) Antibodies specific to Cadherin-17
US10982005B2 (en) Antibodies to bone marrow stromal antigen 1
US20150093392A1 (en) Antibodies
AU2012275271B2 (en) Antibodies to ADP-ribosyl cyclase 2
US20210032360A1 (en) Antibodies against bst1 for preventing or treating myelodysplastic syndrome
US20120231004A1 (en) Antibodies
US20200231694A1 (en) Pharmaceutical combinations comprising an anti-bst-1 antibody and a cytidine analogue
HK1196138B (en) Antibodies to adp-ribosyl cyclase 2
HK1196138A (en) Antibodies to adp-ribosyl cyclase 2
OA16799A (en) Antibodies to ADP-ribosyl cyclase 2.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526